Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Branched-Chain Amino Acids (BCAAs)—leucine, isoleucine, and valine—have been studied for their potential to support individuals with Acquired Immune Deficiency Syndrome (AIDS), primarily due to the muscle wasting (cachexia) and protein-energy malnutrition associated with HIV/AIDS. Several clinical studies have assessed BCAA supplementation in this context. Some small trials have indicated that BCAA supplementation can help maintain or increase lean body mass in HIV-infected individuals, possibly by stimulating muscle protein synthesis when overall calorie and protein intake is inadequate. There is also limited evidence suggesting BCAAs may help modulate immune function, although this effect is not well established in the context of HIV/AIDS. However, the overall evidence base is limited by small sample sizes, short study durations, and methodological limitations. Reviews and guidelines from major organizations such as the World Health Organization or the U.S. Department of Health and Human Services do not recommend BCAAs as a standard therapy for HIV/AIDS-associated wasting, instead emphasizing overall nutritional support and antiretroviral therapy. In summary, the use of BCAAs in AIDS is based on plausible physiological rationale and some preliminary scientific studies, but robust, large-scale, high-quality evidence is lacking. Therefore, while there is some scientific interest and limited validation, BCAA supplementation is not a widely endorsed or conclusively supported therapy for AIDS-related wasting or immune support.

More about Branched-Chain Amino Acids
More about Acquired Immune Deficiency Syndrome

Other ingredients used for Acquired Immune Deficiency Syndrome

Other health conditions supported by Branched-Chain Amino Acids

Products containing Branched-Chain Amino Acids